Switching biologics in children with psoriasis: Results from the BiPe cohort.
adalimumab
adolescents
biologics
children
etanercept
psoriasis
ustekinumab
Journal
Pediatric dermatology
ISSN: 1525-1470
Titre abrégé: Pediatr Dermatol
Pays: United States
ID NLM: 8406799
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
revised:
28
09
2021
received:
15
07
2021
accepted:
09
10
2021
pubmed:
11
12
2021
medline:
4
2
2022
entrez:
10
12
2021
Statut:
ppublish
Résumé
There is currently little information on switching biologics in pediatric psoriasis. To evaluate the real-world clinical practice and safety of switching biologics in the "Biological Treatments for Pediatric Psoriasis" (BiPe) cohort. Data for all 134 patients included in the BiPe cohort were analyzed. A further evaluation of the subpopulation of patients who switched from a first-line biologic to a second-line biologic was then conducted. Drug survival rates were also compared between biologics given as first-line or second-line agents. Overall, 29 patients (female: 55%; mean age: 16.6 ± 3.0 years) switched between two biologics. Etanercept (ETN) was the first-line biologic used in 23 patients: 16 (69.6%) switched to adalimumab (ADA) and seven (30.4%) to ustekinumab (UST). Six patients received first-line ADA and switched to UST. Loss of efficacy (62.1%), primary inefficacy (20.7%), and parental choice (6.9%) were the main reasons for switching biologics. One (3.4%) of the switches was performed because of adverse events or intolerance. For UST and ADA, the 18-month drug survival rate did not differ according to whether the agent was given as a first-line or second-line biologic (UST: P = .24; ADA: P = .68). No significant differences in drug survival rates were observed between the three different switches (ADA to UST, ETN to ADA, and ETN to UST). Our study provided key insights into the real-life clinical practice of switching biologics in pediatric psoriasis patients. However, more information and guidance on switching biologics in pediatric psoriasis are needed to improve real-life practice and outcomes.
Sections du résumé
BACKGROUND
BACKGROUND
There is currently little information on switching biologics in pediatric psoriasis.
OBJECTIVE
OBJECTIVE
To evaluate the real-world clinical practice and safety of switching biologics in the "Biological Treatments for Pediatric Psoriasis" (BiPe) cohort.
METHODS
METHODS
Data for all 134 patients included in the BiPe cohort were analyzed. A further evaluation of the subpopulation of patients who switched from a first-line biologic to a second-line biologic was then conducted. Drug survival rates were also compared between biologics given as first-line or second-line agents.
RESULTS
RESULTS
Overall, 29 patients (female: 55%; mean age: 16.6 ± 3.0 years) switched between two biologics. Etanercept (ETN) was the first-line biologic used in 23 patients: 16 (69.6%) switched to adalimumab (ADA) and seven (30.4%) to ustekinumab (UST). Six patients received first-line ADA and switched to UST. Loss of efficacy (62.1%), primary inefficacy (20.7%), and parental choice (6.9%) were the main reasons for switching biologics. One (3.4%) of the switches was performed because of adverse events or intolerance. For UST and ADA, the 18-month drug survival rate did not differ according to whether the agent was given as a first-line or second-line biologic (UST: P = .24; ADA: P = .68). No significant differences in drug survival rates were observed between the three different switches (ADA to UST, ETN to ADA, and ETN to UST).
CONCLUSION
CONCLUSIONS
Our study provided key insights into the real-life clinical practice of switching biologics in pediatric psoriasis patients. However, more information and guidance on switching biologics in pediatric psoriasis are needed to improve real-life practice and outcomes.
Substances chimiques
Biological Products
0
Ustekinumab
FU77B4U5Z0
Adalimumab
FYS6T7F842
Etanercept
OP401G7OJC
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
35-41Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Mahé E. Childhood psoriasis. Eur J Dermatol. 2016;26(6):537-548.
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol. 2010;162(3):633-636.
Tollefson MM, Crowson CS, McEvoy MT, Maradit KH. Incidence of psoriasis in children: a population-based study. J Am Acad Dermatol. 2010;62(6):979-987.
Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB. Systemic treatment of recalcitrant pediatric psoriasis: a case series and literature review. J Drugs Dermatol. 2015;14(8):881-886.
Bronckers IMGJ, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147-1157.
Pfizer. Enbrel (etanercept) summary of product information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf. Accessed March 9, 2021
Abbvie. Humira (adalimumab) summary of product information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf. Accessed March 9, 2021
Janssen-Cilag. Stelara (ustekinumab) summary of product information. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000958/WC500058513.pdf. Accessed March 9, 2021
Phan C, Beauchet A, Burztejn AC, et al. Biological treatments for paediatric psoriasis: a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol. 2019;33(10):1984-1992.
Phan C, Beauchet A, Burztejn AC, et al. Evaluation of children with psoriasis from the BiPe cohort: are patients using biotherapies in real life eligible for phase III clinical studies? Paediatr Drugs. 2019;21(3):169-175.
Ramos Pinheiro R, Diamantino F, Cabete J, Brasileiro A, Baptista J, Lopes MJP. Switching biologics in severe pediatric psoriasis: a retrospective analysis. Int J Dermatol. 2017;56(12):1461-1464.
Wang TS, Tsai TF. Biologics switch in psoriasis. Immunotherapy. 2019;11(6):531-541.
Özkur E, Kıvanç Altunay İ, Oğuz Topal İ, et al. Switching biologics in the treatment of psoriasis: a multicenter experience. Dermatology. 2021;237(1):22-30.
Smith CH, Anstey AV, Barker JN, et al. British association of dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol. 2009;161(5):987-1019.
Hu Y, Chen Z, Gong Y, Shi Y. A review of switching biologic agents in the treatment of moderate-to-severe plaque psoriasis. Clin Drug Investig. 2018;38(3):191-199.
Bayaraa B, Imafuku S. Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University psoriasis registry. J Dermatol. 2019;46(5):389-398.
Honda H, Umezawa Y, Kikuchi S, et al. Switching of biologics in psoriasis: reasons and results. J Dermatol. 2017;44(9):1015-1019.
Warren RB, Smith CH, Yiu ZZN, et al. Differential drug survival of biological therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADIR). J Invest Dermatol. 2015;135(11):2632-2640.
Menting SP, Sitaram AS, Bonnerjee-van der Stok HM, de Rie MA, Hooft L, Spuls PI. Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis. Br J Dermatol. 2014;171(4):875-883.